Article Sidebar

pdf
Date Published: 15/05/2024
Abstract Views: 102
Views pdf: 58
DOI: https://doi.org/10.51298/vmj.v538i3.9638
Issue
Vol. 538 No. 3 (2024)
Section
Các bài báo
How to Cite
Trần, T. V., Nguyễn, B. T., Lê, T. V., & Lê, T. A. (2024). THE VALUE OF THE NEUTROPHIL TO LYMPHOCYTE RATIO IN NON-SMALL CELL LUNG CANCER PATIENTS. Vietnam Medical Journal, 538(3). https://doi.org/10.51298/vmj.v538i3.9638

THE VALUE OF THE NEUTROPHIL TO LYMPHOCYTE RATIO IN NON-SMALL CELL LUNG CANCER PATIENTS

Thành Vinh Trần, Bảo Trân Nguyễn, Thượng Vũ Lê, Tuấn Anh Lê

Main Article Content

Abstract

Introduction: The neutrophile to lymphocyte ratio based on complete blood cell count results pretreatment can be a potential biomarker to support clinicians in the prognosis of patients with non-small cell lung cancer. Objectives: Prognostic role of pretreatment neutrophil to lymphocyte ratio in patients with non-small cell lung cancer. Methods: A descriptive cross-sectional study with longitudinal follow-up on 169 patients confirmed non-small cell lung cancer at all stages and treated at the Oncology Center at Cho Ray Hospital from October 2022 to September 2023. Results: Patients in the group with NRL≥2.71 had a lower progression-free survival time than patients in the NLR<2.71 group: 9.1 months versus 10.3 months (p<0.001). In multivariate analyses, the neutrophil to lymphocyte ratio was an independent prognostic factor for progression-free survival in non-small cell lung cancer patients. Conclusions: NLR pretreatment as a potential biomarker for follow-up and prognostic in patients with non-small cell lung cancer

Article Details

Keywords

non-small cell lung cancer, NSCLC, NLR (neutrophil to lymphocyte ratio), prognostic, progression-free survival (PFS).

References

1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. 10.3322/caac.21660.
2. Tran HTT, Nguyen S, Nguyen KK, et al. Lung Cancer in Vietnam. J Thorac Oncol. 2021; 16(9):1443-1448. 10.1016/j.jtho.2021.06.002.
3. Powell DR and Huttenlocher A. Neutrophils in the Tumor Microenvironment. Trends Immunol. 2016; 37(1):41-52. 10.1016/j.it.2015.11.008.
4. Grivennikov SI, Greten FR and Karin M. Immunity, inflammation, and cancer. Cell. 2010; 140(6):883-99. 10.1016/j.cell.2010.01.025.
5. Uribe-Querol E and Rosales C. Neutrophils in Cancer: Two Sides of the Same Coin. J Immunol Res. 2015; 2015:983698. 10.1155/2015/983698.
6. Yuan C, Li N, Mao X, Liu Z, Ou W and Wang SY. Elevated pretreatment neutrophil/white blood cell ratio and monocyte/lymphocyte ratio predict poor survival in patients with curatively resected non-small cell lung cancer: Results from a large cohort. Thorac Cancer. 2017; 8(4):350-358. 10.1111/1759-7714.12454.
7. Phan TT, Ho TT, Nguyen HT, Nguyen HT, Tran TB and Nguyen ST. The prognostic impact of neutrophil to lymphocyte ratio in advanced non-small cell lung cancer patients treated with EGFR TKI. Int J Gen Med. 2018; 11:423-430. 10.2147/IJGM.S174605.
8. Liu J, Li S, Zhang S, et al. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab. J Clin Lab Anal. 2019; 33(8):e22964. 10.1002/ jcla.22964.